TAK700

Phase III Trial Comparing Orteronel (TAK-700) Plus Prednisone Against Placebo Plus Prednisone Fails

Reporting both negative clinical trial results is as important as reporting positive results. However, pharmaceutical companies often bury negative results. Fortunately (actually unfortunately because there were negative results) a Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed [...]

By Malecare|2020-02-04T11:36:51-05:00April 3rd, 2015|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, TAK700, Uncategorized|0 Comments

TAK-700 Fails to Offer A Survival Extension

Much of my reporting about ASCO 2014 has included only positive studies, but there is always a share of studies and trials that do not prove to be of a direct positive value to men with Advanced Prostate Cancer. Today’s report includes one of these negative reports. Remember, a negative report is as valuable as [...]

By Malecare|2021-02-17T11:03:12-05:00June 9th, 2014|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, TAK700, Uncategorized|1 Comment

Takeda Un-blinds & Halts the Phase 3 Study of Orteronel in Men with mCRPC That Progressed Post-Chemotherapy

A press release made yesterday brought some bad news to the advanced prostate cancer community. Takeda Pharmaceutical Company Limited (“Takeda”) announced that it has un-blinded and stopped the ELM-PC 5 Phase 3 study (C21005) of orteronel plus prednisone compared to placebo plus prednisone in patients with metastatic, castration- resistant prostate cancer (mCRPC) that had progressed [...]

By Malecare|2017-10-19T10:49:37-04:00July 26th, 2013|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, TAK700|0 Comments

Attacking Androgen Receptor Signaling In Castrate Resistant Prostate Cancer

Advanced prostate cancer eventually progresses and becomes castration resistant (CRPC) despite the fact that it is exquisitely sensitivity to androgen deprivation therapy. There has been recent evidence that prostate cancer progression at the CRPC stage is still mediated by androgen receptor signaling, so it seems that subsequent androgen receptor targeting may further contribute to disease [...]

By Malecare|2017-10-19T10:51:57-04:00October 20th, 2011|abiraterone acetate, Advanced Prostate Cancer, Drugs & Treatments, Hormone Therapy, MDV3100, On The Horizon, TAK700, Uncategorized, Understanding APC|0 Comments

New Approved Drugs Keep Us in the Proverbial Pickle

Over the last year or so we have seen a marked change in the treatment landscape for men with castrate resistant advanced prostate cancer. The FDA has approved sipuleucel-T (Provenge), cabazitaxel (Jevtana) and last week it also approved abiraterone (Zytiga). This changed landscape of multiple treatment options creates new problems, of course good problems. Prostate [...]

By Malecare|2011-05-06T11:30:13-04:00May 6th, 2011|abiraterone acetate, Advanced Prostate Cancer, Cabazitaxel, Chemo Therapy, Chemo Therapy Failure, Drugs & Treatments, General Information, How We Live, On The Horizon, Prostate Ponderings, Provenge, Research, TAK700, Uncategorized, Understanding APC|3 Comments

Finally, A New Phase III Clinical Trial to Open Evaluating TAK-700

Finally, some good news as Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited have announced their intention to start a Phase III clinical trial of TAK-700 in the U.S. for men with advanced prostate cancer. TAK-700, which I have been writing about under the heading of “On the Horizon,” is [...]

By Malecare|2017-10-19T10:53:26-04:00November 18th, 2010|Advanced Prostate Cancer, Hormone Therapy, On The Horizon, TAK700, Uncategorized|1 Comment

On The Horizon – A Status Report of Six New Promising Advancing Treatments for Men with Advanced Prostate Cancer as of the Beginning of June, 2010

As of today there are many different potential drugs undergoing phase III evaluations for men with advanced prostate cancer, some of them seem to offer great hope and promise. Considering we just had Provenge finally approved, this is great news. […]

By Malecare|2010-06-08T09:15:34-04:00June 8th, 2010|abiraterone acetate, Advanced Prostate Cancer, Alpharadin (radium-223), Cabazitaxel, Chemo Therapy, Clinical Trials, Clinical Trials, Drugs & Treatments, FDA, General Information, Hormone Therapy, MDV3100, On The Horizon, Prostate Ponderings, Prostvac, Research, TAK700, Uncategorized, Understanding APC|3 Comments